|Articles|November 9, 2011

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-11-09-2011
  • Volume 7
  • Issue 11

Technical Perspectives from CPhI Worldwide

Pharmaceutical Technology's podcast series from CPhI.

Patricia Van Arnum, senior editor of Pharmaceutical Technology, discusses strategies in optimizing API syntheses and manufacturing. Participants include Jan-Olav Henck, PhD, chief scientific officer at Aptuit, Fred Fleitz, senior manager of process R&D with Cambridge Major Laboratories, and Roger McDonald, director of business development with Cambridge Major Laboratories. Also, Annemieke Timmers, CPhI brand director with UBM, discusses CPhI Worldwide, which was held in Frankfurt in October 2011 and other CPhI events.

Listen here to a podcast with Jan-Olav Henck, PhD, chief scientific officer at Aptuit, who discusses strategies and considerations in polymorph screening.

Listen here to a podcast with Fred Fleitz, senior manager, process R&D with Cambridge Major Laboratories, and Roger McDonald, director of business development with Cambridge Major Laboratories, discuss recent project work in optimizing several API syntheses. Fleitz discusses the approach taken in a condensation reaction between a naphthoquinone derivative and a substituted methyl vinyl ketone. McDonald discusses the optimization of a synthetic route for a complex natural product analogue. In another project, he discusses an approach taken to maintain the desired enantioselectivity of a molecule containing a chiral cyclopropane moiety during scale-up.

Listen here to a podcast with Annemieke Timmers, CPhI brand director with UBM, discusses CPhI Worldwide, which was held in Frankfurt in October 2011, and other CPhI events.

Articles in this issue

Related to this article

Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.